# A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

> **NCT06048315** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Degan Lu** · enrollment: 52 (estimated)

## Conditions studied

- Lung Cancer
- TKI Resistance
- EGFR Sensitive Mutation
- Anlotinib
- Pianzumab

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Penpulimab

## Key facts

- **NCT ID:** NCT06048315
- **Lead sponsor:** Degan Lu
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06048315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06048315, "A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06048315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*